BetterLife Pharma: Patented, Differentiated and Premium Quality Cannabinoid-based Nutraceuticals and Pharmaceuticals
Dr Toni Rinow, CEO With a substantial impact on industries as diverse as cosmetics, food and beverage, and pharmaceuticals, the cannabis market is growing at breakneck speed, backed by verifiable accolades, myriad of use cases, analysis, and forecasts. According to the reports, the legal international cannabis market is poised to grow more than 1000 percent within the next ten years. A significant part of this growth will be accredited to the usage of cannabis in pharmaceutical products for treating medical conditions, such as cancer, Parkinson’s disease, Alzheimer’s disease, arthritis, and several neurological conditions. With more states legalizing cannabis for recreational and medicinal use, there can be no argument that innovative companies stand to play an important role in democratizing access to medical cannabis through a wide range of products. One such firm, BetterLife Pharma is poised to become a strategic winner in this exploding market. BetterLife Pharma is one of the pioneering companies that is bringing a wide array of medicinally beneficial over the counter products to the market. The company is on a mission to capitalize on key cannabis markets in the United States, Canada, and the European Union and become a leader in the nutraceutical, OTC, and medical wellness market using patent-protected drug delivery technologies.
"We are adding value to products in the nutraceutical, OTC, and medical wellness market using patent protected drug delivery technologies"
Unlike many cannabis companies that develop products that can be consumed through inhalation, BetterLife Pharma is introducing a range of products that can be administered through oral, sublingual, topical, and transdermal methods. Their product line includes vegan capsules, dissolvable tablets, topical creams and gels, intimate lubricants, roll-on pain relievers, stick packs, and bulk powder for the pharmaceutical market. The companyhas strategically structured its business into three divisions: BetterLife Pharma Pharmaceuticals, BetterLife Pharma Green Stream, and BetterLife Pharma Naturals. This helps the company streamline its operations efficiently and achieve its organizational milestones through procurement, manufacturing, and supply and distribution.
Ensuring Safety through Patented Technology
Albeit proven benefits, the uncertainty surrounding the safety and efficacy of cannabis is a longstanding concern in the industry. “We are still in the period when consumers extract hemp oil on their own,” says Dr. Toni Rinow, CEO of BetterLife Pharma. As cannabis shops crop up across thestates, it is important to consider the quality, efficacy, and safety and compliance of products. Moreover, the current cannabis derivatives leave much to be desired when it comes to parameters such as taste, effectiveness, bioavailability, and stability.
BetterLife leverages its expanding drug delivery IP portfolio and customized formulation capabilities to develop products in compliance with the highest quality standards. From procuring the raw materials to developing the final product, the company rigorously adheres to industry practices and compliance regulations.
Dr Wolfgang Renz, Chief Medical Officer
BetterLife has acquired worldwide rights to proprietary drug delivery technologies that allow them to deliver and commercialize cannabis products. Through this, the company plans to establish a global footprint for its product portfolio of water-soluble, shelf-stable, and advanced bioavailable CBD (Cannabidiol) formulations. CBD is one of the two abundant cannabinoids obtained from a cannabis plant; the other one is tetrahydrocannabinol (THC).
Our formulation technology provides significantly higher bioavailability and stability compared to alternative oil-based formulations
Bioavailability, the measure of the potency of a cannabis product, differs depending on the intake methods such as sublingual, inhalation, oral, topical, transdermal, and suppositories. The more bioavailable a dosage is, the lower the quantity required to experience the effects. Wolfgang Renz, Chief Medical Officer at BetterLife Pharma, says, “Simply put, it is critical to think about how much of the product will make into our system. Our formulation technology provides significantly higher bioavailability and stability compared to alternative oil-based formulations.” For example, BetterLife Pharma applies one of its patented technology to bring one of its flagship products, micellized CBD oral solution to the market. The product contains high-quality and pure extracts of natural hemp oil with CBD content greater than 99.0 percent and THC content less than 0.2 percent, which is hard to attain by traditional ways of synthesis. The product proves to be effective as it has bioavailability up to 10 times higher than the products of its competitors. In addition to that, the superior stability of theproduct gives it a shelf life over a year. By enhancing the uptake of water-insoluble ingredients and keeping lipid-soluble compounds trapped in micelles, the patented technology enables them to significantly increase the uptake of these molecules from the intestine.
Driving BetterLife Pharma’s pleasure products is the transdermal technologies— THRUDERMIC, for CBD delivery, a patented drug delivery technology making use of more convenient and less invasive administration routes including as dermal, vaginal, rectal, and nasal. THRUDERMIC, is a technology developed in Israel that can precisely formulate various cannabinoids to control and prolong their release while maintaining steady therapeutic concentrations.
BetterLifePharma also has the technological capability to extract cannabis oil with superior quality; the final extract contains nearly 95 percent of cannabinoids.
By employing an ecologically friendly process RTIC (Ready to Infuse Cannabis), and utilizing supercritical extracting methods, the company brings a cleaner, safer, and a purer way to extract the essential oil. The purified ingredients can be infused into multiple GMO-free substrates to allow homogenized blending into almost any food or beverage ingredient. The process enables them to introduce capsules, stick packs, bulk powder, beverages, and baked goods to the highly competitive cannabis market.
BetterLife relies on ready to use active cannabis substances and turns it into specific formulations. They leverage their in-house as well as the external capacity for production and also avail the services of partners for some critical manufacturing processes. Partners utilize BetterLife Pharma’s technology for manufacturing products on their behalf. In addition to that, the company has in-house production capacity in Canada.
Expanding in Abundance
Going forward, BetterLife Pharma foresees a strong demand for the development of cannabinoids for a variety of different purposes. In the field of medicine, they have identified some of the critical medical conditions, including multiple sclerosis, seizure treatment, pain management, and anti-emesis in oncology, that require cannabinoid-based drugs as substitutes. BetterLife Pharma’s team is pushing the envelope to bring transdermal nanotechnology for cannabinoids to achieve optimal formulations with high cannabinoid concentration. The company has already engaged in discussions with one of the biggest hemp manufacturers involved in transdermal applications. With that, they aim to make a big leap into the treatment of Parkinson’s, as well as Alzheimer’s diseases.
Citing the company’s expansion plans, Toni says they are currently focusing on the U.S., the Canadian and European markets. Germany is the company’s test market in Western Europe, and they are successfully running a pilot program in another test market, the Slovak Republic and the Check Republic in Central Europe. Recently, BetterLife Pharma has acquired iAmHealth, an online nutraceutical distribution and sales platform that serves the EU market. This acquisition will allow BetterLife Pharma to bring the products directly to patients and consumers through the online store.
Betterlife Pharma understands that the cannabis industry is way different from the typical pharmaceutical sector. “We believe that when it comes to key competencies in this landscape, innovation leads the market, and for that reason, we focus more on R&D,” mentions Kevin Roland, Vice President, Chemical Manufacturing and Control, BetterLife Pharma. The company has also hired a team of doctors, engineers, and market experts to bring a unique combination of market experience and technological prowess while extending their product line.
From an R&D perspective, Toni contemplates that the process of drug delivery has always aimed at improving the existing generic drugs. BetterLife Pharma has set a new vision in the market that focuses on changing the status quo. By bringing innovative methods in the drug delivery process, the company has revolutionized nutraceutical, over-the-counter, medical wellness market alongside using better raw materials, ingredients, and new synthesizing processes to develop better products.
Headquarters Costa Mesa, CA, Montreal, Canada; Vaduz, Lichtenstein
Management Dr Toni Rinow, CEO and Dr Wolfgang Renz, Chief Medical Officer
Description BetterLife Pharma Pharmaceuticals is poised to become a strategic winner in this exploding market. BetterLife Pharma is on a mission to capitalize key cannabis markets in Canada, United States, and the European Union. In combination with a solid merger and acquisition strategy, the organization strives to become a leader in the pharmaceutical, OTC, nutraceutical and wellness markets. BetterLife Pharma adds value to products in the nutraceutical, OTC, and medical wellness market using patent protected drug delivery technologies
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: